Professional Documents
Culture Documents
Consequences and Management of Hyperphosphatemia in Patients With Renal Insufficiency
Consequences and Management of Hyperphosphatemia in Patients With Renal Insufficiency
S1–S7
Consequences and management of hyperphosphatemia in pa- by parathyroid gland hyperplasia and increased syn-
tients with renal insufficiency. Progressive renal insufficiency thesis of parathyroid hormone (PTH) [3]. Secondary
leads to hyperphosphatemia, hypocalcemia, and secondary hyperparathyroidism is usually quadraglandular, and re-
hyperparathyroidism. Bone demineralization in secondary
hyperparathyroidism may induce fractures, while joint and sults from the combined effect of altered calcium phos-
subcutaneous precipitations of calcium pyrophosphate limit phate metabolism and vitamin D production. In addition
mobility, and may cause crippling. Strategies to preempt bone to increased phosphate retention, patients with ESRD
and joint destruction in chronic kidney disease and end-stage have reduced production of active vitamin D, resulting in
renal disease have focused on limiting dietary phosphorus, hypocalcemia and increased PTH. Over time, these fac-
intra-gut binding of ingested phosphorous, enhancing calcium
absorption, and limiting parathyroid hormone secretion. De- tors result in parathyroid gland hyperplasia, autonomous
ciding which regimen is most effective to meet these treatment production of PTH, and tertiary hyperparathyroidism [4].
objectives challenges nephrologists; they often uncover conflict- Figure 1 outlines multiple factors involved in the patho-
ing evidence about which abnormal metabolite should be the genesis of secondary hyperparathyroidism, including low
prime treatment objective. Especially vexing is the question of levels of vitamin D, hypocalcemia, altered parathyroid
whether hypercalcemia is a cardiotoxic consequence of calcium-
based phosphate binders. gland function, and skeletal resistance to PTH. High
levels of circulating PTH result in bone loss and other
systemic defects, such as cardiovascular complications
Chronic kidney disease inducing progressive decrease that increase mortality in patients with renal failure. The
in renal function is estimated by an expert committee of metabolism of calcium, phosphorous, and vitamin D plays
the National Kidney Foundation [1] to occur in about 20 an important role in secondary hyperparathyroidism.
million individuals in the United States. Chronic renal Impaired renal production of 1,25-dihydroxyvitamin D
failure results in reduced synthesis of vitamin D by the (calcitriol), the active hormonal form of vitamin D, con-
kidneys and increased retention of phosphorus. Distur- tributes to the generation and maintenance of secondary
bances in calcium and phosphorous metabolism in pa- hyperparathyroidism in patients with CKD [5]. Calcitriol
tients with chronic kidney disease (CKD) can result in represses parathyroid cell proliferation and PTH syn-
secondary hyperparathyroidism, along with ensuing bone thesis. CKD patients have reduced levels of calcitriol,
disease, soft tissue and vascular calcification, as well as which results in high serum PTH levels [6]. Calcitriol
arterial stiffness and artherosclerosis [2]. This review will deficiency results in indirect secondary hyperparathy-
focus on the consequences of secondary hyperparathy- roidism due to decreased intestinal absorption of calcium.
roidism in the context of CKD. The challenges in treating The progression of CKD, as determined by glomeru-
altered mineral metabolism and the resulting renal and lar filtration rates, is associated with decreased levels of
cardiac complications will also be discussed. 1,25-dihydroxyvitamin D and a corresponding increase
in PTH levels, as shown in Figure 2 [7]. In this report,
CKD and secondary hyperparathyroidism PTH levels were compared in 58 diabetic and 268 nondi-
abetic patients with serum creatinine levels >1.2 mg/dL.
In patients with end-stage renal disease (ESRD), Diabetic patients with creatinine clearance <70 mL/min
kidney failure results in decreased secretion and in- had lower PTH levels than did nondiabetic patients
creased retention of phosphate. This causes hyperphos- (P = 0.003), as well as significant differences in serum
phatemia, a condition that results in the development phosphorus, magnesium, and tubular resorption of phos-
of secondary hyperparathyroidism and renal osteodys- phate. Serum glucose concentration in those with dia-
trophy. Secondary hyperparathyroidism is characterized betes varied inversely with PTH, leading to the inference
that poor control of diabetes (hyperglycemia) may con-
C 2005 by the International Society of Nephrology tribute to development of hypoparathyroidism in patients
S-1
S-2 Friedman: Consequences and management of hyperphosphatemia
←←
Hypocalcemia
←
Renal Mass
1,25(OH)2D Current Elevated Current
Phosphorus Retention therapy PTH therapy
Set-point
Hyperplasia
Low Calcitriol Levels Altered Parathyroid
Gland Function Renal Nonskeletal Unintended
←←
PO4
←←
1,25(OH)2D PO4
1,25(OH)2D Increased
Skeletal resistance
Mortality
Redrawn from original source (author not certain of origin).
Modified from original source.
Fig. 1. Pathogenesis of secondary hyperparathyroidism. Low levels of
calcitriol (vitamin D), hypocalcemia, altered PTH gland function, and Fig. 3. Clinical consequences of secondary hyperparathyroidism. In-
skeletal resistance to PTH contribute to the pathogenesis of secondary creased risk of cardiovascular and bone disease arises as a result of
hyperparathyroidism in ESRD patients. elevated PTH levels.
100
10 Dialysis Male
Dialysis Female
Annual mortality (%)
Dialysis Black
1 Dialysis White
GP Male
GP Female
0.1 GP Black
GP White
0.01
1.50
Relative Mortality Risk (RR)
1.39**
1.25
1.18*
1.02
1.00 1.00
1.00
1.1-4.5 4.6-5.5 5.6-6.5 6.6-7.8 7.9-16.9
Serum Phosphorus Quintile (mg/dL) Fig. 5. Elevated serum phosphorus levels is
associated with increased risk of mortality in
P=0.03 ''P<0.0001 (N=6407) dialysis patients. Increased serum phosphate
(>6.5 mg/dL) in CKD patients is associated
Am J Kidney Dis 31:607–617, 1998. Modified from original source. with increased risk of mortality.
5-fold higher coronary artery calcium score that corre- D, and bring the calcium concentration back to normal
lated with a lower vertebral bone mass compared with levels.
nondialysis patients. However, no correlation between
serum calcium, phosphate, or PTH levels with the cal-
cium score was seen. Progress in calcification was seen at Management of hyperphosphatemia
a 12-month follow-up of these patients. Higher calcium Increased risk of mortality and secondary hyper-
scores correlated with lower vertebral bone mass in dial- parathyroidism in dialysis patients occurs when the serum
ysis patients. phosphorous levels exceed 6.5 mg/dL and the Ca × P
Due to the prevalence of hyperphosphatemia in ESRD product exceeds 72 mg2 /dL2 . Because of the morbid-
patients, and the associated increased cardiovascular ity and mortality associated with patients with ESRD,
mortality, Ganesh et al studied the mechanism mediat- data available for serum phosphate were analyzed from
ing this risk. Data from two large random samples of pa- two large, random, cross-sectional studies of patients on
tients on hemodialysis (N = 12,833) in the United States hemodialysis for at least 1 year. Data were analyzed for
were used to test the hypothesis that elevated serum phos- patients in the United States Renal Data System, the
phate contributes to cardiac causes of death [17]. A 2- Case Mix Adequacy Study, and the Dialysis Morbidity
year follow-up for the relative risk (RR) of CAD, sudden and Mortality Study Wave [18]. The relative risk (RR) of
death, and other cardiac causes was determined with re- death for patients with serum phosphorus greater than
spect to serum phosphorus, Ca × P product, and serum 6.5 mg/dL was 1.27 compared with those with serum
PTH levels. High cardiovascular mortality was seen in phosphorus levels between 2.4 and 6.5 mg/dL. The link
patients with elevated serum phosphate (>6.5 mg/dL), between higher risk of death and serum phosphorous con-
compared with the low phosporus group (≤6.5 mg/dL). centration, however, was not uniform across all the quin-
Elevated levels of serum P, Ca × P product, and PTH tiles of serum phosphate analyzed. Figure 5 is a graphic
have been implicated in the altered control of phosphate depiction of these data. Patients in the highest 2 quintiles
metabolism. Additionally, serum calcium and calcium- of serum phosphorus are at the greatest risk for mortality.
based binders were not found to be risk factors for car- For example, patients in the serum phosphorus quintiles
diovascular mortality in this report. of 6.6 to 7.8 mg/dL and 7.9 to 16.9 mg/dL are predicted to
have a mortality risk of 1.18 and 1.39, respectively. The
Ca × P product showed a mortality risk trend similar to
that seen with serum phosphorus. However, the analy-
TREATMENT GOALS sis of serum calcium in this study showed no correlation
Because hyperphosphatemia and increased Ca × PO 4 with the relative risk of death. These observations have
products are associated with increased mortality in resulted in recommendations that serum phosphorous be
dialysis patients, it is important to effectively manage controlled between 2.5 and 6.5 mg/dL, and the Ca × P be
and treat hyperphosphatemia and the resulting hyper- maintained at less than 52 mg2 /dL2 [18].
parathyroidism in patients with CKD. The aim of the The most effective means of controlling hyperphos-
strategy for prevention and treatment should be 3-fold: phatemia is managing dietary phosphorous intake. A
to reduce hyperphosphatemia and the pathogenesis of typical American diet provides approximately 1300 mg
phosphate retention, restore synthesis of active vitamin of phosphorous daily from a protein-rich meal. The
Friedman: Consequences and management of hyperphosphatemia S-5
recommended dietary allowance for phosphorus is 700 tion and death. Goodman et al used EBCT to screen for
mg/day. Increased dietary intake of phosphorus , com- coronary-artery calcification in 39 young patients with
bined with elevated serum phosphorous levels resulting ESRD (mean age 19 years) compared with 60 normal in-
from altered mineral metabolism in dialysis patients, are dividuals [22]. This study reports an increase in the mean
associated with vascular and visceral calcification. A re- serum phosphorus concentration and the Ca × P prod-
cent study involving 63 dialysis patients showed the effec- uct in serum of ESRD patients with coronary calcifica-
tiveness of dietary education in controlling hyperphos- tion. The daily intake of calcium-containing phosphate
phatemia [19]. At the onset of the study, patients had binders was nearly twice as great in ESRD patients with
mean serum phosphorous levels >6 mg/dL. A significant cardiac calcification as in those patients without calcifica-
difference (P < 0.01) in serum phosphorus (6.8 ± 0.72 tion. These observations suggest that the long-term expo-
mg/dL and 5.2 ± 1.2 mg/dL before and after 6 months of sure to alterations in mineral metabolism seen in ESRD
education, respectively) and in the Ca × P product levels patients, and the subsequent efforts to treat and correct
(61 ± 7.7 mg2 /dL2 and 47 ± 11 mg2 /dL2 before and af- these alterations may contribute to coronary artery cal-
ter 6 months of counseling, respectively) was observed in cification in young adults.
the group of patients who had received dietary counsel- An alternative phosphate binder that is not aluminum-
ing and educational tools, compared with a control group or calcium-based is sevelmer hydrochloride, a quater-
of patients (phosphorus: 7.2 ± 1.3 mg/dL and 6.7 ± 1.7 nary amine anion exchange resin that binds phosphate
mg/dL before and after 6 months education, respectively; ions and releases hydrochloric acid [23]. A randomized
Ca × P product: 62 ± 9.6 mg2 /dL2 and 60 ± 14.3 mg2 /dL2 52-week “Treat-to-Goal ” trial compared sevelamer hy-
before and after 6 months of education, respectively). drochloride to two calcium-containing phosphate binders
However, dietary phosphorous restriction and in a group of 200 hemodialysis patients [24]. The primary
hemodialysis are often not effective in adequately end point of this trial was to achieve Ca × P product tar-
controlling serum phosphorous, and phosphate binders get levels, and to estimate calcification of the coronary
have been routinely prescribed to reduce the intestinal arteries using a calcification score from EBCT measure-
absorption of phosphorous. Various estimates of patient ments. Both sevelamer hydrochloride and the calcium-
compliance indicate that the side effects of constipation based phosphate binders provided equivalent control of
and nausea may cause as many as one half of a dialysis serum phosphorus. However, serum calcium concentra-
population to discontinue regular use of phosphate tion, hypercalcemia, and an increased absolute calcium
binders. Although aluminum-based phosphate binders score in coronary arteries were seen in patients treated
have been effectively used in reducing levels of serum with calcium, but not with sevelamer.
phosphorus, the risk of toxicity due to aluminum absorp- These data contrasted with those reported in the Cal-
tion is high. Increased incidence of aluminum-induced cium Acetate Renagel Evaluation (CARE) study (dis-
bone disease, osteomalacia, encephalopathy, and mi- cussed by Dr. Nolan in this supplement). The CARE
crocytic anemia seen in CKD patients has resulted study compared the efficacy and safety of calcium acetate
in abandoning the use of aluminum-based phosphate and sevelamer hydrochloride in the treatment of hyper-
binders [20]. phosphatemia in CKD patients [25]. In this 8-week trial,
Calcium-based phosphate binders have been effec- treatment with calcium acetate was found to be more
tive in combination with vitamin D, and have replaced effective in controlling serum phosphorous and Ca × P
aluminum-binders worldwide; calcium acetate is the product levels than treatment with sevelamer hydrochlo-
binder of choice in the United States, and calcium carbon- ride. Side effects were similar for patients treated with
ate is used extensively in Europe [21]. The efficacy and calcium acetate or sevelamer hydrochloride.
cost effectiveness of calcium-based binders have been In a recent review, Coladonato et al suggest that the
outweighed by concern for the long-term safety of these warnings of putative dangers associated with calcium-
agents. These agents have a risk of metastatic calcifica- containing phosphate binders appear to be premature in
tion, particularly if taken with vitamin D analogues, and the context of risk versus benefits of calcium-containing
are prescribed when a high dialysate calcium concentra- phosphate binders [26]. The need for prospective, ran-
tion is employed. The major advantage of calcium-based domized control trials to examine the pathobiology of
phosphate binders is their low cost, and long experience in coronary calcification in CKD and ESRD patients is
their use for “hyperacidity” with minimal toxicity to those essential. Studies that examine differences in the rates
who have been treated daily with proprietary antacids for of calcification in calcium-containing and calcium-free
a decade or longer. phosphate binders, when controlling hyperphosphatemia
However, the debate about the safety of calcium-based and hyperparathyroidism, would help resolve some of
phosphate binders continues. Treating dialysis patients these issues. A recommendation is made on the im-
with these agents results in a higher oral calcium in- portance of having outcome-based trials, using clini-
take, conferring an additional risk of coronary calcifica- cal cardiac events as primary outcomes—along with
S-6 Friedman: Consequences and management of hyperphosphatemia
thorough scientific research—before abandoning the use serum phosphorus levels in dialysis patients because hy-
of calcium-containing phosphate binders. perphosphatemia and the elevated Ca × P correlate with
cardiovascular mortality and bone disease. Currently,
Restoring vitamin D and calcium levels both sevelamer and calcium-containing phosphate
binders (calcium acetate and calcium carbonate) are ac-
In an attempt to restore vitamin D levels, patients with
ceptable first-line therapeutic agents in the treatment of
CKD are also treated with vitamin D derivatives. Until
ESRD patients with hyperphosphatemia. Cost-benefit
recently, high doses of oral calcium supplements and/or 1-
analysis, and the superior efficacy of calcium acetate
a-hydroxylated vitamin D derivatives were the mainstay
in controlling serum phosphorous, make it a treatment
of treatment of secondary hyperparathyroidism in CKD.
choice for initial treatment of ESRD patients. Seve-
However, these treatments may not be well tolerated due
lamer hydrochloride, the noncalcium-, nonaluminum-
to the associated vascular and soft tissue calcification. An
containing phosphate binder is the preferred treatment
association between vascular calcification and the use of
choice for patients who develop persistent hypercal-
vitamin D therapy has been reported [27]. To circumvent
cemia during treatment with the calcium-based phos-
the adverse effects observed with vitamin D therapy, cal-
phate binders. This treatment, however, has the potential
cimimetic agents are under development.
risk of acid loading in ESRD patients.
Sevelamer hydrochloride and calcium acetate are the
Calcimimetics only two drugs approved by the FDA in the treatment of
Calcimimetic agents modulate the activity of the hyperphosphatemia in dialysis patients. Ongoing studies
calcium-sensing receptor, and result in profound reduc- with calcimimetic agents will offer alternate therapeutic
tions in levels of circulating PTH. Additionally, these choices for patients with CKD.
agents result in decreases in serum calcium, phospho- Reprint requests to Eli A. Friedman, Department of Medicine, Down-
rus, and Ca × P product [28]. A recent study with the state Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203.
second generation calcimimetic agent, cinacalcet HCl, E-mail: elifriedmn@aol.com
confirms that this agent represents a safe and effective
novel therapy with the potential to dramatically alter the REFERENCES
treatment and complications associated with secondary 1. SUGARMAN JR, FREDERICK PR, FRANKENFIELD DL, et al: Dialysis
hyperparathyroidism in patients on dialysis. Block et al Outcomes Quality Initiative Clinical Practice Guidelines. Develop-
ing clinical performance measures based on the Dialysis Outcomes
report the observations from two randomized double- Quality Initiative Clinical Practice Guidelines: Process, outcomes,
blind placebo trails evaluating the safety and effective- and implications. Am J Kidney Dis 42:806–812, 2003
ness of cinacalcet in hemodialysis patients who were 2. MICHAEL M, GARCIA D: Secondary hyperparathyroidism in chronic
kidney disease: Clinical consequences and challenges. Nephrol Nurs
unable to control the secondary hyperparathyroidism J 31:185–194, 2004
despite standard treatment [29]. Patients received 3. GOODMAN WG: The consequences of uncontrolled secondary hyper-
cinacalcet (N = 371) or placebo (N = 370) for a period of parathyroidism and its treatment in chronic kidney disease. Semin
Dial 17:209–216, 2004
26 weeks. The once-daily dosage was increased from 30 4. SILVER J: Pathogenesis of parathyroid dysfunction in end-stage renal
mg to 180 mg to achieve intact PTH levels of 250 pg/mL or disease. Adv Ren Replace Ther 9:159–167, 2002
less. The primary end point was percent of patients with 5. SLATOPOLSKY E, BROWN A, DUSSO A: Pathogenesis of secondary
hyperparathyroidism. Kidney Int 73(Suppl):S14–S19, 1999
PTH levels in this range during a 14-week efficacy assess- 6. BROWN AJ, DUSSO A, SLATOPOLSKY E: Vitamin D. Am J Physiol
ment. Mean PTH levels decreased 43% in patients receiv- 277:F157–F175, 1999
ing cinacalcet compared with controls (P < 0.001). The 7. MARTINEZ I, SARACHO R, MONTENEGRO J, et al: A deficit of cal-
citriol synthesis may not be the initial factor in the pathogenesis of
Ca × P product decreased 15% in the cinacalcet treated secondary hyperparathyroidism. Nephrol Dial Transplant 11(Suppl
group compared with the placebo control group (P < 3):22–28, 1996
0.001) [29]. The development of calcimimetic agents may 8. SILVER J, KILAV R, NAVEH-MANY T: Mechanisms of secondary hy-
perparathyroidism. Am J Physiol Renal Physiol 283:F367–F376,
dispel the controversy that has prevailed over the use of 2002
calcium-based phosphate binders in conjunction with vi- 9. MOZ Y, SILVER J, NAVEH-MANY T: Characterization of cis-acting ele-
tamin D therapy. ment in renal NaPi-2 cotransporter mRNA that determines mRNA
stability. Am J Physiol Renal Physiol 284:F663–F670, 2003
10. MALLUCHE HH, MAWAD H, MONIER-FAUGERE MC: The importance
of bone health in end-stage renal disease: Out of the frying pan, into
CONCLUSION the fire? Nephrol Dial Transplant 19(Suppl 1):i9–i13, 2004
Hypocalcemia, hyperphosphatemia, and reduced vita- 11. AKHTAR I, GONZALEZ EA: Biologic effects of parathyroid hormone
metabolites: Implications for renal bone disease. J Investig Med
min D seen in patients with CKD are associated with 52:51–57, 2004
elevated levels of PTH and secondary hyperparathy- 12. SILVER J, BUSHINSKY D: Harnessing the parathyroids to create
roidism. The clinical consequences of increased PTH stronger bones. Curr Opin Nephrol Hypertens 13:471–476, 2004
13. FOLEY RN, PARFREY PS, SARNAK MJ: Clinical epidemiology of car-
levels include renal osteodstrophy, systemic and arterial diovascular disease in chronic renal disease. Am J Kidney Dis
effects that increase mortality. It is important to control 32:S112–S119, 1998
Friedman: Consequences and management of hyperphosphatemia S-7
14. FOLEY RN, PARFREY PS, SARNAK MJ: Epidemiology of cardiovas- 22. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery cal-
cular disease in chronic renal disease. J Am Soc Nephrol 9(12 cification in young adults with end-stage renal disease who are un-
Suppl):S16–23, 1998 dergoing dialysis. N Engl J Med 342:1478–1483, 2000
15. KOK M, CASE D, BILLINGSLY J: The use of bone scintigraphy to eval- 23. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hy-
uate metastatic calcification caused by end-stage renal disease and drochloride] (RenaGel): A noncalcemic phosphate binder for the
secondary hyperparathyroidism. Clin Nucl Med 28:144–145, 2003 treatment of hyperphosphatemia in chronic renal failure. Am J Kid-
16. BRAUN J, OLDENDORF M, MOSHAGE W, et al: Electron beam com- ney Dis 29:66–71, 1997
puted tomography in the evaluation of cardiac calcification in 24. CHERTOW GM, BURKE SK, RAGGI P, et al, FOR THE TREAT TO GOAL
chronic dialysis patients. Am J Kidney Dis 27:394–401, 1996 WORKING GROUP: Sevelamer attenuates the progression of coronary
17. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated and aortic calcification in hemodialysis patients. Kidney Int 62:245–
serum PO(4), Ca x PO(4) product, and parathyroid hormone with 252, 2002
cardiac mortality risk in chronic hemodialysis patients. J Am Soc 25. QUNIBI WY, HOOTKINS RE, MCDOWELL LL, et al: Treatment of hy-
Nephrol 12:2131–2138, 2001 perphosphatemia in hemodialysis patients: The Calcium Acetate
18. BLOCK GA, HULBERT-SHEARON TE, et al: Association of serum phos- Renagel Evaluation (CARE Study). Kidney Int 65:1914–1926, 2004
phorus and calcium x phosphate product with mortality risk in 26. COLADONATO JA, SZCZECH LA, FRIEDMAN EA, et al: Does calcium
chronic hemodialysis patients: A national study. Am J Kidney Dis kill ESRD patients—The skeptic’s perspective. Nephrol Dial Trans-
31:607–617, 1998 plant 17:229–232, 2002
19. FORD JC, POPE JF, HUNT AE, et al: The effect of diet education on 27. MALLICK NP, BERLYNE GM: Arterial calcification after vitamin-D
the laboratory values and knowledge of hemodialysis patients with therapy in hyperphosphatemic renal failure. Lancet 2:1316–1320,
hyperphosphatemia. J Ren Nutr 14:36–44, 2004 1968
20. REINKE CM, BREITKREUTZ J, LEUENBERGER H: Aluminum in over- 28. BLOCK GA: The impact of calcimimetics on mineral metabolism and
the-counter drugs: Risks outweigh benefits? Drug Saf 26:1011–1025, secondary hyperparathyroidism in end-stage renal disease. Kidney
2003 Int 87(Suppl):S131–S136, 2003
21. NOLAN CR, QUNIBI WY: Calcium salts in the treatment of hyper- 29. BLOCK GA, MARTIN KJ, DE FRANCISCO AL, et al: Cinacalcet for sec-
phosphatemia in hemodialysis patients. Curr Opin Nephrol Hyper- ondary hyperparathyroidism in patients receiving hemodialysis. N
tens 12:373–379, 2003 Engl J Med 350:1516–1525, 2004